Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ST-01156 · 1 trial · 4 indications
To characterize the safety, tolerability, and adverse event (AE) profile of escalating doses of ST-01156 administered for 5 consecutive days followed by 2 days without study drug administration every 7 days, with a cycle defined as 28 days (4 weeks).
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | ST-01156, administered orally once daily for 5 consecutive days followed by 2 days without study drug administration every 7 days |
| Name | Type | Description |
|---|---|---|
| ST-01156 | DRUG | ST-01156 is an orally administered degrader of RBM39, a protein frequently upregulated in cancer |
Inclusion Criteria: * Age ≥ 18 years on the day of signing the consent form, except for adolescents with Ewing Sarcoma or other malignancies for which there is a biological rationale to support participation, in which case the participant is ≥ 16 years old. * Has a metastatic or locally advanced an...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ST-01156 is an investigational small molecule being studied for the treatment of advanced solid tumors, including Ewing sarcoma, hepatocellular carcinoma (HCC), and biliary tract cancer (BTC). It is currently in Phase 1 clinical development and has not been approved by the FDA.
ST-01156 is a small molecule RBM39 degrader. It works by degrading the RBM39 protein, which is involved in RNA splicing and cancer cell survival. This mechanism is being evaluated in patients with advanced solid malignancies.
ST-01156 is being developed by BeyondSpring, Inc., a biopharmaceutical company listed on NASDAQ under the ticker BYSI. The company is conducting a Phase 1/1B clinical trial of the drug in the United States.
ST-01156 is in Phase 1 clinical development. It is currently being evaluated in a Phase 1/1B study that is recruiting patients with advanced solid tumors. The drug has not been approved by the FDA and remains investigational.
ST-01156 is being studied in a single active clinical trial, NCT07197554, titled 'A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies.' The trial is recruiting 171 participants in the United States and is not randomized or blinded.
ST-01156 is a distinct investigational compound developed by BeyondSpring, Inc. It is a small molecule RBM39 degrader and is not known to be the same as any other marketed drug. It has received orphan drug and breakthrough therapy designations from the FDA.